APTEVO THERAPEUTICS INC.

Analyst Reco. Aptevo Therapeutics Inc.

Equities

APVO

US03835L3069

Market Closed - Nasdaq Other stock markets 01:30:00 11/05/2024 am IST			5-day change	1st Jan Change
0.89 ^USD	-4.81%		0.00%	0.00%

08/05	Aptevo Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
11/04	US Equity Markets Close Mixed After March Producer Price Inflation Data	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Wall Street Set to Open Higher as Investors Await Inflation Data, Fed Rate Decision in Coming Days	12/22/12	MT
US Futures Move Modestly Higher Monday Ahead of Inflation Data Tuesday, Fed Rate Decision Meeting Conclusion Wednesday	12/22/12	MT
Aptevo Therapeutics Inc. Announces APVO436, in Combination with Venetoclax and Azacitidine, Achieved a 100% Clinical Benefit Rate in Venetoclax Treatment Naïve AML Patients	12/22/12	CI
Piper Sandler Adjusts Price Target on Aptevo Therapeutics to $20 From $69, Reiterates Overweight Rating	13/22/13	MT
Roth Capital Adjusts Aptevo Therapeutics' Price Target to $36 From $50, Reiterates Buy Rating	15/21/15	MT
APTEVO THERAPEUTICS : Roth Capital Adjusts Aptevo Therapeutics PT to $50 From $64, Maintains Buy Rating	28/21/28	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW